Autism

Current Location

115 Autism Trials Near You

Power is an online platform that helps thousands of Autism patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
The present study aims to adapt and evaluate the feasibility of the BeatIt-2 behavioral activation intervention for people with intellectual disabilities and low mood to be implemented with minimally verbal autistic individuals.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

15 Participants Needed

The purpose of the research is to determine if changes seen during sulforaphane treatment (a compound that comes from eating certain vegetables) can better be understood using digital biomarkers. These digital biomarkers are things like heart rate, muscle movement etc. and are measured using non-invasive devices (like a watch) and are aimed at complementing the traditional clinical scores already in use in current trials (e.g. Aberrant Behavior Checklist (ABC), Social Responsiveness Scale (SRS) and Ohio Autism Clinical Impressions Scale (OACIS)).
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:13 - 30
Sex:Male

10 Participants Needed

Employment Program for Autism

East Hanover, New Jersey
The investigators are looking to evaluate how effective a training program that focuses on character strengths may be in improving job maintenance skills in young adults. The investigators are examining the effects of this intervention in young adults who feel they would like to help in improving their satisfaction with work, and in keeping their jobs.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:14 - 26

30 Participants Needed

The investigators are looking to evaluate how effective a strength-based intervention may be in improving job interview skills in young adults. The investigators are examining the effects of this intervention in young adults who may have difficulty with job interviews, and who may want to improve these skills.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:14 - 26

30 Participants Needed

DHA for Autism

Piscataway, New Jersey
Dr. Sherie Novotny of the Department of Psychiatry at UMDNJ-RWJMS and collaborators are starting a treatment trial to determine whether Docosa Hexanoic Acid(DHA), the major omega-3 fatty acid found in the brain and a component of fish oil, has any effects on the symptoms of autism. We propose to carry out a trial to test the effect of DHA compared to a placebo (a pill with no drug in it) on several aspects of autism in children and adolescents, in a 12-week clinical study with children or adolescents in the age group of 5-17 with a diagnosis of Autism Spectrum Disorder. Additionally this trial will study genes related to the therapeutic agent, DHA, and biomarkers related to DHA in the urine.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:5 - 17

132 Participants Needed

The purpose of this study is to examine whether cerebellar stimulation can be used to improve cognitive deficits and mood in patients with schizophrenia, autism, bipolar disorder, Parkinson's disease, and major depression.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

200 Participants Needed

This trial is testing a daily pill called tasimelteon to help children and adults with Autism Spectrum Disorder (ASD) who have trouble sleeping. The medication aims to improve sleep by helping to regulate the body's internal clock.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:2 - 65

100 Participants Needed

Vagus Nerve Stimulation for Autism

Staten Island, New York
The goal of this flexible single-subject design vagus nerve stimulation (VNS) study is to examine the behavioral, cognitive, and biorhythmic effects of VNS in children and adults with autism and developmental disabilities. The main aims are: * Pilot the creation of a profile for those who will respond to VNS with the long-term goal of designing clinical trials. * Examine the effects of VNS on a broad range of symptoms. Participants will select between 1, 2, or 3 months of daily VNS treatment and complete study visits each month.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:12 - 40

75 Participants Needed

Ballet Program for Autism

New York, New York
This study will be a randomized trial that will examine the impact of a recreational ballet program on children with autism spectrum disorder (ASD). The research team are primarily interested in assessing changes in motor skills with secondary objectives focused on the social, psychological, and behavioral effects. The study will aim to collect data from 24 participants with ASD. Participants must be 7-12 years old, have a confirmed diagnosis of ASD, and speak English or Spanish. All participants will be enrolled in a 12 week ballet program. The ballet program is based off the curriculum and structure of Ballet for All Kids, a non-profit organization that has been tailoring ballet classes for children with ASD for over one decade. All research team members and volunteers will be trained in the BFAK program's curriculum and structure. Ballet instruction and all research materials will be provided in both English and Spanish. The research team will randomize the sample into an intervention group and waitlist control. The research team will measure outcomes through validated self-reports that caregivers will complete. For the intervention group, questionnaires will be completed at baseline and throughout the intervention (weeks 4, 8, and 12). For those in the waitlist control group, questionnaires will be completed at baseline, throughout the intervention group's ballet classes, and throughout their own participation in the program. Results of this study will help to determine if how a recreational ballet program can impact the motor, psychological, social, and behavioral skills of a child with ASD, informing the direction of future research and interventions.

Trial Details

Trial Status:Active Not Recruiting
Age:7 - 12

24 Participants Needed

The goal of this research is to explore abilities to learn word meanings from overheard conversations in children with ASD (and, as a control, typically developing children). Specific Aim 3 (Experiment 3): Determine whether children with ASD can learn verbs and pronouns by overhearing. Most prior work on learning from overheard speech has focused on learning nouns that label objects. This experiment extends this work to study other kinds of words.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:24 - 71

179 Participants Needed

This trial studies if children with ASD can learn new words from video calls, either by being spoken to directly or by overhearing conversations. It aims to improve educational methods for these children.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

295 Participants Needed

Speech Exposure for Autism

New York, New York
The goal of this research is to explore abilities to learn word meanings from overheard conversations in children with ASD (and, as a control, typically developing children). Specific Aim 1 (Experiment 1): Subaim 1a: Identify child characteristics associated with learning from overhearing. In a prior study, the investigators found that 13 children with ASD were able to learn the meanings of novel words that they heard used in a conversation involving two adults. In the current study, the investigators aim to study a larger sample to identify what child characteristics are associated with good learning in an overhearing situation as compared to a situation in which the child is directly taught the new word. Subaim 1b: Assess retention and generalization of words learned from overhearing. The investigators will re-test children on their knowledge of the word meanings after a 10-minute delay to see if they both retain the word meanings and can generalize the new words to new situations.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

155 Participants Needed

This trial aims to study the efficacy and safety of cannabidivarin (CBDV) in children with ASD.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:5 - 18

100 Participants Needed

This trial tests a program to help toddlers with autism improve their social and communication skills. The program starts with play-based activities and is adjusted based on each child's progress. These activities have been shown to improve social communication in young children with autism. The goal is to find the best way to support these children in everyday settings.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:24 - 36

350 Participants Needed

Leucovorin for Autism

Brooklyn, New York
This trial tests a liquid form of leucovorin calcium in young children with autism spectrum disorder (ASD) to see if it improves their social communication and behavior. The study focuses on children who have significant social and communication challenges. The treatment aims to enhance brain function, potentially leading to better communication and interaction skills.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:30 - 60

80 Participants Needed

This trial is testing a liquid form of leucovorin calcium to see if it can help young children with autism improve their language skills and behavior. The study involves young children who have autism and language delays. The treatment aims to enhance brain function and development. Leucovorin calcium has shown potential benefits in improving verbal communication and behavior in children with autism spectrum disorder (ASD) who test positive for cerebral folate receptor autoantibodies.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:30 - 60

80 Participants Needed

This trial will test if growth hormone can help children with Phelan-McDermid syndrome and idiopathic autism. Researchers hope it will improve their social skills, language, and reduce repetitive behaviors. The study will involve 45 children who will receive daily injections for a few months. Growth hormone has been previously tested in children with Phelan-McDermid syndrome, showing good tolerance without serious issues.

Trial Details

Trial Status:Enrolling By Invitation
Age:2 - 12

45 Participants Needed

JASPER Intervention for Autism

White Plains, New York
This trial is testing JASPER, a play-based therapy, on young children with autism who have limited verbal skills. The therapy uses guided play to help these children improve their social and communication abilities. JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a naturalistic developmental behavioral intervention that has been found effective for promoting social communication in young children with autism.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 5

90 Participants Needed

Pimavanserin for Autism

White Plains, New York
This Phase 2 study examines the safety, tolerability, and preliminary efficacy of pimavanserin in individuals with Autism Spectrum Disorder. Male or female participants aged 16 to 40 years of age will be randomized to receive single doses of either placebo or pimavanserin in this randomized, placebo-controlled, cross-over designed study, followed by open label extension.
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:16 - 40

30 Participants Needed

The proposed project will attempt to confirm the benefits of a structured magic trick training program (MTTP) experience in adolescents with autism. Benefits of participating in a 6-week virtual MTTP will be evaluated using validated assessments to measure social-emotional competencies.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:11 - 18

60 Participants Needed

Why Other Patients Applied

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38
Children with Autism Spectrum Disorder (ASD) and insomnia, and their parent(s) will undergo 4 sessions of behavioral therapy for sleep problems followed by 4 bimonthly booster sessions. Children and their families will be randomly assigned to one of three conditions: cognitive behavioral therapy (in-person), cognitive behavioral therapy (remote), or behavioral therapy (remote). Arousal will be measured through heart-rate variability. Sleep and secondary outcomes (child daytime behavior, parent sleep) will be collected at baseline (weeks 1-2 before starting the treatment), post-treatment (weeks 6-8 from baseline), 6-month follow-up, and 12-month follow-up.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:6 - 12

180 Participants Needed

The purpose of the study is to evaluate the use of autologous Bone Marrow Derived Stem Cells (BMSC) as a means to improve cognitive impairment as occurs in Alzheimer's Disease and other dementias and to improve behavior and socialization issues which occur in adult Autism Spectrum Disorder. The use of Near Infrared Light, in conjunction with the use of BMSC, will also be assessed.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased

100 Participants Needed

The purpose of this study is to explore whether a non-invasive form of ear stimulation called transcutaneous auricular vagus nerve stimulation (taVNS) can manage symptoms in patients with autism spectrum disorder (ASD). Additionally, this study also uses magnetic resonance imaging (MRI) to capture images of participants' brains and apply an image processing method called INSCAPE to track brain state changes during taVNS treatment in ASD. Investigators will recruit up to 16 participants with ASD.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:12 - 17

16 Participants Needed

Investigators will recruit up to 10 patients with Anxiety comorbid with Autism Spectrum Disorder (ASD) from the outpatient clinics at MUSC. This pilot trial will be an open-label investigation of the safety and feasibility of transcutaneous auricular vagus nerve stimulation (taVNS) as a nonpharmacological wearable intervention used to manage anxiety and other neuropsychiatric symptoms at home, with patients/caretakers self-administering treatments. Each subject will undergo an initial in-person screening and be consented prior to participating in the study. This will be followed by an in-person training session with the subject (and caretaker if applicable), where they will learn how to self-administer taVNS and ask any pertinent questions. Participants will self-administer taVNS at home twice daily for 4 weeks. These treatments will not interfere with other aspects of their mental health care. Our investigators, over the prior 8 years, have demonstrated that taVNS is safe and feasible in the outpatient setting. Furthermore, investigators have recently demonstrated that taVNS is well tolerated and safely self-administered at home with remote monitoring. The investigators hypothesize that taVNS will be safe and feasible to administer at home in this new population. Results from this study may lead to further exploration of taVNS in this unique population.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:12 - 17

10 Participants Needed

The purpose of this research study is to evaluate a time-limited version of Parent Child Interaction Therapy (PCIT) delivered via telehealth for young children with autism spectrum disorder (ASD) and disruptive behavior problems. Families will be randomly assigned to receive 10 sessions of Tele-PCIT or Treatment as Usual. Families will complete a baseline assessment, a post-treatment assessment, and a 3-month follow-up.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:2 - 83

80 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Autism clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Autism clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Autism trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Autism is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Autism medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Autism clinical trials?

Most recently, we added Bedtime Routine for Autism, Caregiver Training for Autism Spectrum Disorder and Cognitive Behavioral Therapy for Anxiety in Autism to the Power online platform.

Is there still a spectrum for autism?

Yes—medical guidelines still call it Autism Spectrum Disorder, but experts no longer picture that spectrum as a single line from “mild” to “severe.” Instead, it’s more like a sound-mixing board with many sliders: social communication, repetitive behaviors, sensory sensitivity, thinking style, and support needs can each sit at different points, creating a unique profile for every autistic person. Clinicians note these differences by assigning support levels (1-3) in each domain so interventions can be tailored rather than ranked.

What is the biggest symptom of autism?

There isn’t one “biggest” symptom of autism; doctors look for a pattern that includes BOTH social-communication differences (like trouble reading body language or carrying on back-and-forth conversation) and restricted, repetitive behaviours or intense interests/sensory sensitivities (such as needing strict routines or reacting strongly to noises). Which of these stands out most varies from person to person, so if you notice a persistent mix of them, the next step is to talk with your GP or a psychologist for a formal autism assessment and tailored support.

Can maternal stress cause autism?

Normal day-to-day worries during pregnancy have not been proven to cause autism. Large studies show that only very severe or long-lasting stress (such as the death of a close relative or a natural disaster) is linked to a small rise in risk—about 2 % to roughly 3 %—and even that link may partly reflect other genetic or environmental factors. Taking steps to manage high stress is good for overall maternal and baby health, but parents should not blame themselves or everyday stressors if a child is later diagnosed with autism.

What is the life expectancy of someone with autism?

Large registry studies (e.g., Sweden 2016, Denmark 2022) find that autistic people, on average, die 15–20 years earlier than non-autistic peers, with a median age of death around the mid-50s; the figure is lower (≈ 40s) when someone also has intellectual disability or uncontrolled epilepsy and higher (late 50s or beyond) when those conditions are absent. The gap is driven less by autism itself than by treatable or preventable issues—seizures, heart disease, accidents and suicide—so good medical follow-up, mental-health support and safety planning can help many autistic individuals live into typical older age.

What is the best treatment for autism in the world?

There is no one “best” treatment for every person with autism; the strongest evidence shows that progress comes from an individualized program that blends proven developmental-behavioral therapies (such as Applied Behavior Analysis or other naturalistic approaches) with speech-language and occupational therapy, parent coaching, and tailored educational supports. A multidisciplinary team adjusts this mix over time—and may add medication for anxiety, ADHD, or sleep problems—so the plan fits the person’s specific strengths, challenges, and goals, which is what international guidelines recommend for the best results.

Is autism overdiagnosed?

Rates of autism have risen sharply (e.g., from about 1 in 150 U.S. children in 2000 to 1 in 36 today), but most of that jump comes from broader definitions, better screening, and shifting other labels to “autism,” not from a sudden epidemic. Studies suggest roughly 1 in 10 people once given the label later lose it—evidence of some over-diagnosis—yet girls, adults, and many minority children are still frequently missed, so the real problem is uneven diagnosis rather than simply “too much” or “too little.” A careful, multidisciplinary assessment that also checks for ADHD, language disorders, anxiety, and other look-alike conditions is the best way to get an accurate answer for any individual.

Who carries the autism gene?

There is no single “autism gene.” Autism risk comes from a mix of many common genetic variants, rare mutations, and sometimes new (de-novo) changes that neither parent had; these can be inherited from either mother or father, while factors like higher paternal age and the female-protective effect can influence how that risk shows up. In short, either parent—or neither, if the change is new—can pass along genetic risk, so talking with a genetic counselor is the best way to understand a specific family’s situation.

Which state has the highest rate of autism?

In the latest CDC ADDM study, the surveillance area in California recorded the highest autism rate: roughly 4.5 % of 8-year-olds (about 45 children per 1,000). However, ADDM covers only parts of 11 states and other tracking systems use different methods, so rankings can change if you look at school records, insurance data, or adult estimates—meaning the numbers are useful for spotting trends, not declaring a single “most-autistic” state.

Has anyone ever overcome autism?

Autism is a lifelong neuro-developmental difference, so people don’t “overcome” it in the sense of being cured; instead, most continue to be autistic throughout life. With early, individualized supports and ongoing accommodations, many children and adults make major gains—some even lose the formal diagnosis—yet they often keep certain autistic traits and still benefit from understanding and acceptance. The practical aim is therefore not to erase autism but to build skills, reduce distress, and create environments where each autistic person can thrive.

What was autism called in the 1980s?

In the early-1980s diagnostic manual (DSM-III, 1980) autism was officially listed as “Infantile Autism,” and in the 1987 revision (DSM-III-R) the name was changed to “Autistic Disorder” under the larger category of “Pervasive Developmental Disorders.” Outside the U.S., doctors using the World Health Organization’s ICD-9 still called it “Childhood Autism.” In everyday practice, people might also have heard “Kanner’s autism” or “childhood psychosis,” but the two formal labels you would have seen on a medical chart during that decade were “Infantile Autism” at the start of the 1980s and “Autistic Disorder” by the end.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security